News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
638,288 Results
Type
Article (31635)
Company Profile (688)
Press Release (605965)
Section
Business (197756)
Career Advice (2086)
Deals (36409)
Drug Delivery (93)
Drug Development (77849)
Employer Resources (161)
FDA (15248)
Job Trends (14574)
News (333431)
Policy (28930)
Tag
Academia (1241)
Alliances (47202)
Alzheimer's disease (1159)
Approvals (15174)
Artificial intelligence (124)
Bankruptcy (364)
Best Places to Work (10733)
Biotechnology (473)
Breast cancer (110)
Cancer (1007)
Cardiovascular disease (90)
Career advice (1720)
Cell therapy (235)
Clinical research (62387)
Collaboration (382)
Compensation (194)
COVID-19 (2129)
C-suite (104)
Data (1083)
Diabetes (144)
Diagnostics (6102)
Earnings (81618)
Employer resources (139)
Events (106677)
Executive appointments (314)
FDA (15742)
Funding (339)
Gene therapy (168)
GLP-1 (583)
Government (2805)
Healthcare (15710)
Infectious disease (2209)
Inflammatory bowel disease (107)
Interviews (419)
IPO (16993)
Job creations (4228)
Job search strategy (1433)
Layoffs (474)
Legal (7253)
Lung cancer (162)
Manufacturing (187)
Medical device (13336)
Medtech (13341)
Mergers & acquisitions (19480)
Metabolic disorders (397)
Neuroscience (1448)
NextGen Class of 2024 (5936)
Non-profit (1869)
Northern California (1473)
Obesity (228)
Opinion (222)
Patents (103)
People (55726)
Pharmaceutical (136)
Phase I (19540)
Phase II (27845)
Phase III (20694)
Pipeline (457)
Postmarket research (1958)
Preclinical (7867)
Radiopharmaceuticals (250)
Rare diseases (215)
Real estate (5745)
Regulatory (20033)
Research institute (1279)
Resumes & cover letters (329)
Southern California (1278)
Startups (3875)
United States (13487)
Vaccines (518)
Weight loss (175)
Date
Today (124)
Last 7 days (779)
Last 30 days (3791)
Last 365 days (36056)
2024 (33084)
2023 (40304)
2022 (50705)
2021 (54007)
2020 (50921)
2019 (41844)
2018 (31980)
2017 (32466)
2016 (30616)
2015 (36068)
2014 (28902)
2013 (23906)
2012 (25494)
2011 (25659)
2010 (23634)
Location
Africa (667)
Arizona (126)
Asia (41375)
Australia (6601)
California (3403)
Canada (1273)
China (250)
Colorado (146)
Connecticut (156)
Europe (86147)
Florida (420)
Georgia (114)
Illinois (284)
Indiana (205)
Kansas (92)
Maryland (490)
Massachusetts (2751)
Michigan (168)
Minnesota (278)
New Jersey (963)
New York (947)
North Carolina (785)
Northern California (1473)
Ohio (123)
Pennsylvania (822)
South America (1058)
Southern California (1278)
Texas (477)
Washington State (377)
638,288 Results for "daiichi sankyo company ltd".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Policy
Arbitration Dispute Between Daiichi Sankyo and Seagen Ends
A dispute between Daiichi Sankyo Co., Ltd. (TSE: 4568) and Seagen Inc. is now concluded and Seagen has paid Daiichi Sankyo approximately U.S. $47 million in connection with attorneys’ fees and costs plus interest awarded by the arbitrator of the party’s dispute.
June 28, 2024
·
1 min read
Business
RevolKa Signed Master Service Agreement with Daiichi Sankyo
RevolKa Ltd., a venture-backed biotech company providing a game-changing protein engineering technology platform signed a master service agreement with Daiichi Sankyo Co., Ltd.
May 27, 2024
·
2 min read
Drug Development
AstraZeneca, Daiichi Sankyo ADC Misses Endpoint in Phase III NSCLC Study
AstraZeneca and Daiichi Sankyo’s investigational antibody-drug conjugate Dato-DXd failed to significantly improve overall survival in non-small cell lung cancer patients versus docetaxel.
May 28, 2024
·
2 min read
·
Tristan Manalac
Patents
Daiichi Sankyo Wins $47M in ADC Patent Arbitration With Seagen, Pfizer Dispute Looms
Daiichi Sankyo has secured a victory in its patent arbitration with Seagen, nabbing a $47 million award for attorneys’ fees and other costs, plus interest. However, a larger patent battle with Pfizer remains.
July 1, 2024
·
2 min read
·
Tristan Manalac
Policy
Daiichi Sankyo Wins $47M in ADC Patent Arbitration With Seagen, Pfizer Dispute Looms
Daiichi Sankyo has secured a victory in its patent arbitration with Seagen, nabbing a $47 million award for attorneys’ fees and other costs, plus interest. However, a larger patent battle with Pfizer remains.
July 1, 2024
·
2 min read
·
Tristan Manalac
Press Releases
Daiichi Sankyo to Showcase TURALIO® Research in Patients with Tenosynovial Giant Cell Tumor at CTOS
November 13, 2024
·
10 min read
Antibody-drug conjugate (ADC)
Merck, Daiichi Score Late-Stage NSCLC Win for ADC, Flag Two Deaths
Despite meeting the primary endpoint in a Phase III study, two patients treated with Merck and Daiichi Sankyo’s experimental antibody-drug conjugate died in a Phase III non-small cell lung cancer study, though the deaths have not been linked to patritumab deruxtecan.
September 17, 2024
·
2 min read
·
Tristan Manalac
Business
Mika Health Collaborates with AstraZeneca and Daiichi Sankyo to Deliver AI-Enabled Mobile Support to Women Undergoing Breast Cancer Treatment
Mika Health, a global digital therapeutics developer specializing in meeting the needs of cancer patients, in collaboration with AstraZeneca and Daiichi Sankyo, announced at the HLTH Europe conference, a digital initiative to improve the experience of women receiving breast cancer treatments.
June 18, 2024
·
6 min read
Antibody-drug conjugate (ADC)
AstraZeneca, Daiichi Sankyo’s ADC Flops in Phase III Breast Cancer on Heels of Lung Cancer Stumble
Monday’s failure to improve overall survival in breast cancer “further dents belief” in the companies’ Dato-DXd and “likely complicates regulatory discussions for approval of this indication,” Jefferies analyst Peter Welford wrote in a note to investors.
September 23, 2024
·
3 min read
·
Tristan Manalac
Policy
UK’s NICE Rejects AstraZeneca, Daiichi Sankyo’s Enhertu for NHS Use
Despite its overall survival and disease progression benefits, the U.K.’s drug cost watchdog has declined to recommend AstraZeneca and Daiichi Sankyo’s Enhertu due to a lack of cost-effectiveness.
March 6, 2024
·
2 min read
·
Tristan Manalac
1 of 63,829
Next
